
|Articles|January 1, 2004
Alcon rings NYSE bell; anecortave trials begin
New York-Tim Sear, Alcon Inc.'s chairman, president, and chief executive officer, rang the closing bell of the New York Stock Exchange at 4 p.m. Dec. 4 to celebrate the company's dramatic rise in stock price since its initial public offering.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5